B4-067 Pulmonary Vascular Disease Flashcards

(33 cards)

1
Q

mean pulmonary artery pressure > 20mm Hg by right heart cath

A

pulmonary hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • mean pulmonary arterial pressure > 20 mm Hg
  • PCWP less than 15 mmHg
  • PVR greater than 3 wood units
A

pulmonary arterial hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

3 prostaglandin pathways

A
  1. endothelin
  2. NO pathway
  3. prostacyclin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  • activity through cAMP
  • vasodilator
  • inhibits proliferation of vascular smooth muscle
  • decreases platelet aggregation
A

prostacyclin

PGI2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

in PAH, prostacyclin synthase is […]

A

decreased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

in PAH, endothelin is […]

A

increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  • arterial vasoconstrictor
  • increases sympathetic activity
  • increases systemic vascular resistance
A

endothelin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  • vasodilator
  • inhibits smooth muscle hypertrophy
A

NO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

in PAH, NO is

A

decreased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  • decreased NO and prostacylin
  • increased endothelin 1

lead to vascular injury via

2

A
  • smooth muscle hypertrophy
  • vasocontriction

early intimal proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

PAH eventually causes right ventricular overload, leading to

A

RV failure

cause of death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

symptoms of right sided heart failure

A
  • hepatosplenomegaly
  • JVD
  • ascites
  • weight gain
  • peripheral edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

oral therapies for NO pathway

3

A
  • sildenafil
  • tadalafil
  • riociguat

inhibit PDE-5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

oral therapies for endothelin pathway

3

A
  • bosentan
  • ambrisentan
  • macitentan

endothelin receptor antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

oral therapies for prostacylin pathway

2

A
  • treprostinil
  • selexipag
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

inhaled therapy

1

other one she said no longer used

A

treprostinil

prostacylin pathway

17
Q

infusion therapies

2

A
  • epoprostenol
  • treprostinil

prostacyclin pathway

18
Q
  • pressure related phenomenon
  • LV problems, left sided valve problems, pulmonary vein obstruction
A

cardiogenic pulmonary edema

19
Q
  • leaky capillaries
  • ARDS, HAPE, Opiate OD, etc
A

non cardiogenic pulmonary edema

20
Q

causes of PAH

7

A
  • idiopathic
  • drugs
  • connective tissue disease
  • HIV
  • portal hypertension
  • CHD
  • schistosomiasis
21
Q

the biggest factor in RV adaptation is

22
Q
  • related to increased left side pressures
  • may be exacerbated by volume overload
A

cardiogenic edema

23
Q

what is used to make the definitive diagnosis of pulmonary artery hypertension?

A

right heart cath

24
Q

most common cause of PH in the world

A

schistosomiasis

25
most common cause of PH in US
heart disease
26
most common cause of death in patients with PAH
progressive RV failure and collapse
27
lung transplantation in PAH is reserved for those
failing maximal medical therapy
28
treatment for severe PAH at urgent risk of HF
* parenteral prostacyclin * diurectics * oxygen
29
* mean pulmonary pressure >20 mmHg * wedge pressure <15 mm Hg * pulmonary vascular resistance greater than 3 wood units
PAH group 1
30
what 3 pathways are implicated in the development of PAH
1. nitric oxide 1. prostacyclin 1. endothelin
31
* abdominal distention * hepatomegaly * lower extremity edema | indicate..
right sided heart failure
32
bilateral rales would indicate
pulmonary edema/left sided HF
33
what measures correspond to risk assessment in PAH? | 2
* decreased CO * syncope